Mitochondrial and metabolic-based protective strategies in Huntington’s disease: the case of creatine and coenzyme Q (Q37965763)

reason for preferred rank

26 August 2017

title

Mitochondrial and metabolic-based protective strategies in Huntington’s disease: the case of creatine and coenzyme Q (English)

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

19 December 2024

Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22150069

19 December 2024

0 references

1

Luana Naia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22150069

19 December 2024

3

A. Cristina Rego

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22150069

19 December 2024

author name string

Maria João Ribeiro

2

1 reference

26 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22150069

19 December 2024

publication date

2 December 2011

1 reference

full work available at URL

26 August 2017

https://www.degruyter.com/document/doi/10.1515/rns.2011.060/xml

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

https://www.degruyter.com/document/doi/10.1515/rns.2011.060/pdf

19 December 2024

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Reviews in the Neurosciences

19 December 2024

published in

1 reference

26 August 2017

volume

23

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

13-28

1 reference

Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Dysregulation of CREB activation and histone acetylation in 3-nitropropionic acid-treated cortical neurons: prevention by BDNF and NGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Complex I defect in muscle from patients with Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

NR2A and NR2B receptor gene variations modify age at onset in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The relationship between uric acid levels and Huntington's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Weight loss in Huntington disease increases with higher CAG repeat number

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Antioxidants cannot suppress the lethal phenotype of a Drosophila melanogaster model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin aggregation and toxicity in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Neuroprotective effects of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial bioenergetics and structural network organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Creatine supplementation lowers brain glutamate levels in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Deranged neuronal calcium signaling and Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntington's disease does not appear to increase the risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Loss of normal huntingtin function: new developments in Huntington's disease research

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Normal huntingtin function: an alternative approach to Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin as an essential integrator of intracellular vesicular trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondria, calcium and cell death: a deadly triad in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Impaired PGC-1alpha function in muscle in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Akt is altered in an animal model of Huntington's disease and in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Insulin neuroprotection against oxidative stress in cortical neurons--involvement of uric acid and glutathione antioxidant defenses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin interacts with a family of WW domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial-dependent apoptosis in Huntington's disease human cybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Bioenergetic dysfunction in Huntington's disease human cybrids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mechanisms of neurodegeneration in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Low stability of Huntington muscle mitochondria against Ca2 in R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial defect in Huntington's disease caudate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Modifications of p53 and the DNA Damage Response in Cells Expressing Mutant Form of the Protein Huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Isolation and Characterization of Mitochondrial DNA-less Lines from Various Mammalian Cell Lines by Application of an Anticancer Drug, Ditercalinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Inducible expression of a dominant negative DNA polymerase-gamma depletes mitochondrial DNA and produces a rho0 phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Drug targeting of dysregulated transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Cell and animal models of mtDNA biology: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Progression of symptoms in the early and middle stages of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Myopathy as a first symptom of Huntington's disease in a Marathon runner

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Generation of rho0 cells utilizing a mitochondrially targeted restriction endonuclease and comparative analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin-protein interactions and the pathogenesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Metabolic control through the PGC-1 family of transcription coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Gametic but not somatic instability of CAG repeat length in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The selective vulnerability of striatopallidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Energy deficit in Huntington disease: why it matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Juvenile onset Huntington's disease--clinical and research perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Depletion of mitochondrial DNA by ddC in untransformed human cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

In situ mitochondrial Ca2 buffering differences of intact neurons and astrocytes from cortex and striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial-dependent Ca2 handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Hypothalamic-endocrine aspects in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Normal platelet mitochondrial complex I activity in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Selective defect of in vivo glycolysis in early Huntington's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Platelet Mitochondrial Complex I and I III Activities Do Not Correlate with Cerebral Mitochondrial Oxidative Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Recent advances in understanding the pathogenesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Molecular targets and therapeutic strategies in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Regulation of intracellular trafficking of huntingtin-associated protein-1 is critical for TrkA protein levels and neurite outgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Opinion: What is the role of protein aggregation in neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Exercise increases mitochondrial PGC-1alpha content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Huntington's disease: the current state of research with peripheral tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

A role for huntington disease protein in dendritic RNA granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Proteomic and oxidative stress analysis in human brain samples of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Uncovering the true prevalence of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Abnormal morphology of peripheral cell tissues from patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Polyglutamine repeat length-dependent proteolysis of huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The cybrid model of sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Production of transmitochondrial mouse cell lines by cybrid rescue of rhodamine-6G pre-treated L-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 A

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Clinical correlates of mitochondrial function in Huntington's disease muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Metabolism and function of coenzyme Q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Genetic and environmental factors in the pathogenesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

The oxidative phosphorylation (OXPHOS) system: nuclear genes and human genetic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

21 January 2018

Degenerate mitochondria

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Detection of mitochondrial DNA deletion by a modified PCR method in a 60Co radiation-exposed patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Mitochondrial Dysfunction and Neurodegenerative Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515/RNS.2011.060

Weight loss in early stage of Huntington's disease

21 January 2018

https://api.crossref.org/works/10.1515/RNS.2011.060

43

1 reference

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

49

1 reference

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

50

1 reference

Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

72

1 reference

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

78

1 reference

Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

96

1 reference

Mitochondrial dysfunction in human breast cancer cells and their transmitochondrial cybrids

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

98

1 reference

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

102

1 reference

Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

112

1 reference

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

120

1 reference

Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

121

1 reference

Wild-type huntingtin protects from apoptosis upstream of caspase-3.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

131

1 reference

Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

135

1 reference

Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

142

1 reference

Mitochondria: beyond oxidative phosphorylation

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

143

1 reference

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

145

1 reference

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

161

1 reference

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

177

1 reference

Neuropathological classification of Huntington's disease

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

180

1 reference

Coenzyme Q10: a review of its promise as a neuroprotectant.

19 December 2024

https://api.crossref.org/works/10.1515/RNS.2011.060

185

1 reference

19 December 2024

Identifiers

DOI

10.1515/RNS.2011.060

1 reference

26 August 2017

1 reference